Harrow, INC. (HROW) — SEC Filings

Overview

Harrow, INC. (HROW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: HARROW, INC. filed an 8-K on March 24, 2026, detailing 'Other Events' under Item 8.01 and 'Financial Statements and Exhibits' under Item 9.01. This filing, with accession number 0001493152-26-012279, indicates that the company is providing updated information or disclosing a significant event that s

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 37 neutral, 2 mixed. The dominant filing sentiment for Harrow, INC. is neutral.

Filing Type Overview

Harrow, INC. (HROW) has filed 24 8-K, 6 10-Q, 1 8-K/A, 1 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13D/A, 1 DEFA14A, 3 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

• HARROW Files 8-K on Other Events, Financial Exhibits — 8-K · Mar 24, 2026
  HARROW, INC. filed an 8-K on March 24, 2026, detailing 'Other Events' under Item 8.01 and 'Financial Statements and Exhibits' under Item 9.01. This filing, with
• 8-K Filing — 8-K · Nov 18, 2025
• Harrow Swings to Profit in Q3 on Strong Sales Growth — 10-Q · Nov 10, 2025 Risk: medium
  HARROW, INC. reported a significant increase in product sales, reaching $71,497,000 for the three months ended September 30, 2025, up from $49,019,000 in the pr
• Harrow, Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Oct 6, 2025 Risk: medium
  On October 6, 2025, Harrow, Inc. filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to co
• Harrow, Inc. Files 8-K/A Amendment — 8-K/A · Oct 1, 2025 Risk: low
  Harrow, Inc. filed an amendment (8-K/A) on October 1, 2025, related to events on September 24, 2025. The filing primarily concerns financial statements and exhi
• Harrow, Inc. Enters Material Definitive Agreement — 8-K · Sep 29, 2025 Risk: medium
  On September 26, 2025, Harrow, Inc. entered into a material definitive agreement related to its financial obligations. The company, previously known as Harrow H
• Harrow, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Sep 26, 2025 Risk: medium
  On September 24, 2025, Harrow, Inc. entered into a material definitive agreement related to its senior notes. The company also reported on unregistered sales of
• Harrow, Inc. Appoints BDO USA as New Auditor — 8-K · Sep 19, 2025 Risk: low
  On September 17, 2025, Harrow, Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed BDO USA, P.A. as its new in
• Harrow, Inc. Files 8-K on Financial Obligations — 8-K · Sep 12, 2025 Risk: medium
  On September 8, 2025, Harrow, Inc. entered into a material definitive agreement related to its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027. T
• Harrow, Inc. Files 8-K Report — 8-K · Sep 9, 2025 Risk: low
  On September 8, 2025, Harrow, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclos
• Harrow, Inc. Files 8-K on Financial Obligations — 8-K · Sep 8, 2025 Risk: medium
  On September 5, 2025, Harrow, Inc. entered into a material definitive agreement related to its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027. T
• Harrow, Inc. Announces Director Departure, New CMO, Fiscal Year Change — 8-K · Aug 25, 2025 Risk: medium
  On August 21, 2025, Harrow, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Mark L. Baum and the appointm
• Harrow's Product Sales Soar 67% in Q2, Driving Strong Growth — 10-Q · Aug 11, 2025 Risk: medium
  HARROW, INC. reported a significant increase in product sales for the three and six months ended June 30, 2025. Product sales net for the second quarter of 2025
• Harrow, Inc. Files 8-K Report — 8-K · Jul 17, 2025 Risk: low
  On July 17, 2025, Harrow, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific mater
• Harrow, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 20, 2025 Risk: medium
  On June 18, 2025, Harrow, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific
• Harrow, Inc. Files 8-K Report — 8-K · Jun 9, 2025 Risk: low
  On June 9, 2025, Harrow, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial t
• Harrow, Inc. Q1 2025 10-Q Filing — 10-Q · May 8, 2025 Risk: medium
  Harrow, Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The company's product sales and other revenues for the
• Harrow Inc. Executive Compensation Details Revealed — DEF 14A · Apr 25, 2025 Risk: low
  Harrow, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes aggregate v
• Harrow, Inc. Files 2024 10-K Annual Report — 10-K · Mar 27, 2025 Risk: medium
  Harrow, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Harrow Health, Inc., o
• HARROW, INC. Files 8-K on Financials — 8-K · Mar 17, 2025 Risk: low
  On March 17, 2025, HARROW, INC. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with finan
• Harrow, Inc. Director Departs; Officer Compensation & Filings — 8-K · Jan 21, 2025 Risk: low
  On January 17, 2025, Harrow, Inc. announced the departure of Director Michael J. Enright. The company also reported on compensatory arrangements for certain off
• SC 13G/A Filing — SC 13G/A · Dec 5, 2024
• Harrow, Inc. Q3 Sales Decline to $38.7M — 10-Q · Nov 14, 2024 Risk: medium
  Harrow, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's product sales net for the third quarter of 2024 were $38
• Harrow, Inc. Files 8-K on Senior Notes Agreements — 8-K · Oct 28, 2024 Risk: low
  On October 25, 2024, Harrow, Inc. entered into a material definitive agreement related to its senior notes. Specifically, the company entered into an indenture
• SC 13G/A Filing — SC 13G/A · Oct 8, 2024
• Harrow, Inc. Files 8-K Report — 8-K · Sep 9, 2024 Risk: low
  On September 9, 2024, Harrow, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known a
• Harrow, Inc. Q2 2024 10-Q Filing — 10-Q · Aug 7, 2024 Risk: medium
  Harrow, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported product sales and other revenues, with specific figures for the second qua
• Harrow, Inc. Appoints New Auditor, BDO USA, P.A. — 8-K · Jun 26, 2024 Risk: low
  On June 24, 2024, Harrow, Inc. filed an 8-K report to disclose changes in its certifying accountant. The company's Audit Committee of the Board of Directors dis
• Harrow, Inc. Seeks Shareholder Vote Approval — 8-K · Jun 17, 2024 Risk: low
  On June 14, 2024, Harrow, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates that the company
• Harrow, Inc. Files 10-Q for Q1 2024 — 10-Q · May 13, 2024 Risk: low
  HARROW, INC. (HROW) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Harrow, Inc. reported financial results for the first quarter ended March 31,
• Harrow, Inc. Amends Stake in Eton Pharmaceuticals — SC 13D/A · Apr 30, 2024 Risk: medium
  On April 30, 2024, Harrow, Inc. filed an amendment (Amendment No. 2) to its Schedule 13D regarding Eton Pharmaceuticals, Inc. This filing indicates a change in
• Harrow, Inc. Files Definitive Additional Materials — DEFA14A · Apr 26, 2024 Risk: low
  Harrow, Inc. filed a Definitive Additional Materials (DEFA14A) on April 26, 2024. This filing relates to materials provided to shareholders, likely concerning a
• Harrow Inc. Debt Exchange Offer Early Results — 8-K · Mar 21, 2024 Risk: medium
  On March 20, 2024, Harrow, Inc. announced the early results of its previously announced offer to exchange its 8.625% senior notes due 2026 for new 11.875% senio
• Harrow, Inc. Closes $125M Senior Notes Offering — 8-K · Mar 20, 2024 Risk: medium
  On March 19, 2024, Harrow, Inc. announced the closing of its previously disclosed offering of 8.625% senior notes due 2026. The company successfully raised $125
• Harrow, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 19, 2024 Risk: medium
  HARROW, INC. (HROW) filed a Annual Report (10-K) with the SEC on March 19, 2024. Harrow, Inc. reported its fiscal year 2023 results on March 19, 2024. The compa
• HARROW, INC. Files 8-K, Details Existing Securities — 8-K · Feb 15, 2024 Risk: low
  HARROW, INC. filed an 8-K on February 15, 2024, reporting under "Other Events" and "Financial Statements and Exhibits." The filing identifies the company's comm
• SC 13G Filing — SC 13G · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Opaleye Management Reports 8.7% Stake in Harrow, Inc. — SC 13G/A · Feb 9, 2024 Risk: low
  Opaleye Management Inc. has updated its ownership stake in Harrow, Inc. (formerly Harrow Health, Inc.) as of December 31, 2023. This Schedule 13G/A filing, an a
• BlackRock Discloses Passive Stake in Harrow, Inc. Common Stock — SC 13G · Jan 29, 2024
  BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Harrow, Inc. (formerly Harr
• HARROW Confirms Nasdaq Listings for Common Stock, Senior Notes — 8-K · Jan 29, 2024
  HARROW, INC. filed an 8-K on January 29, 2024, reporting an event that occurred on January 26, 2024. This filing primarily updates the company's registered secu
• Private Capital Management Discloses Passive Stake in Harrow, Inc. — SC 13G · Jan 9, 2024
  Private Capital Management, LLC, a Delaware-based investment firm, has filed an SC 13G indicating its ownership of Harrow, Inc. common stock as of December 31,
• HARROW Reports Agreement Termination, Leadership Changes, Ethics Update — 8-K · Jan 3, 2024
  HARROW, INC. filed an 8-K on January 3, 2024, reporting events from December 28, 2023. The filing indicates the termination of a material definitive agreement,

Risk Profile

Risk Assessment: Of HROW's 33 recent filings, 0 were flagged as high-risk, 17 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Harrow, INC.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $71,497,000
• Net Income: $1,020,000
• EPS: $0.03
• Cash Position: $74,290,000
• Total Debt: $242,874,000

Key Executives

• Mark L. Baum
• Michael J. Ryan
• Michael J. Enright
• James Silverman

Industry Context

Harrow, Inc. operates within the healthcare industry, likely focusing on specialized medical products or services. This sector is characterized by significant R&D investment, stringent regulatory oversight (e.g., FDA), and evolving reimbursement landscapes. Competition can be intense, with established players and emerging innovators vying for market share.

Top Tags

debt (7) · corporate-governance (6) · pharmaceuticals (5) · Pharmaceuticals (4) · financing (4) · financials (4) · amendment (3) · material-definitive-agreement (3) · filing (3) · sec-filing (3)

Key Numbers

• Product Sales, Net (Q3 2025): $71.5M — Increased by 45.8% from $49.0M in Q3 2024, indicating strong revenue growth.
• Net Income (Q3 2025): $1.02M — Swung from a net loss of $4.22M in Q3 2024, marking a significant improvement in profitability.
• Income from Operations (Q3 2025): $14.7M — Increased substantially from $1.32M in Q3 2024, demonstrating improved operational efficiency.
• Net Loss (YTD Q3 2025): $11.77M — Improved from a $24.26M net loss in YTD Q3 2024, showing progress towards overall profitability.
• Notes Payable (Sept 30, 2025): $242.87M — Increased from $219.54M at Dec 31, 2024, reflecting new debt issuance and refinancing activities.
• Loss on Extinguishment of Debt (YTD Q3 2025): $7.75M — A one-time expense related to debt refinancing, impacting net loss.
• Cash and Cash Equivalents (Sept 30, 2025): $74.29M — Increased from $47.25M at Dec 31, 2024, indicating improved liquidity.
• Net Cash from Operating Activities (YTD Q3 2025): $35.45M — A significant positive shift from a $4.42M net cash used in operating activities in YTD Q3 2024.
• Common Shares Outstanding (Nov 10, 2025): 37,037,453 — Reflects share issuance activities, impacting per-share metrics.
• Basic Net Income Per Share (Q3 2025): $0.03 — Positive EPS after a loss of $0.12 in Q3 2024, indicating a return to per-share profitability.
• Senior Notes Due 2026: 8.625% — Indicates a specific debt instrument of the company.
• Senior Notes Due 2027: 11.875% — Indicates another specific debt instrument of the company.
• SIC Code: 2834 — Pharmaceutical Preparations industry
• Senior Notes Interest Rate: 8.625% — Related to 2026 maturity
• Maturity Year: 2026 — Maturity year for 8.625% Senior Notes

Forward-Looking Statements

• {"claim":"Opaleye Management Inc. will likely maintain a significant, but potentially fluctuating, stake in Harrow, Inc. over the next year.","entity":"Opaleye Management Inc.","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

HRRO · ETON

Frequently Asked Questions